Article

Immunohistochemical profile and fluorescence in situ hybridization analysis of diffuse large B-cell lymphoma in northern China.

Department of Pathology, First Hospital of Peking University, Beijing, China.
Archives of pathology & laboratory medicine (Impact Factor: 2.88). 05/2010; 134(5):759-65. DOI: 10.1043/1543-2165-134.5.759
Source: PubMed

ABSTRACT Gene expression profiling of diffuse large B-cell lymphoma using complementary DNA microarrays has revealed 2 major prognostic groups in Western countries: germinal center B-cell-like and nongerminal center B-cell-like lymphomas. Immunohistochemical analysis using antibodies specific for CD10, BCL6, and MUM1 has been proposed as a surrogate for gene expression profiling.
To study the immunohistochemical features of diffuse large B-cell lymphoma cases from northern China because geographic differences for this disease are known to exist.
Morphologic, immunohistochemical, and fluorescence in situ hybridization analyses of 63 cases of diffuse large B-cell lymphoma from northern China.
There were 38 men and 25 women with a median age of 57 years (range, 12-87 years). CD10 was positive in 19 cases (30%), BCL6 was positive in 22 cases (35%), and MUM1 was positive in 32 cases (51%). Twenty-one (33%) cases were germinal center B-cell-like lymphoma, and 42 (67%) were nongerminal center B-cell-like lymphoma. BCL2 was expressed more often in nongerminal center B-cell-like disease versus germinal center B-cell-like disease (60% versus 24%, P = .01) and in nodal versus extranodal (64% versus 30%, P = .01) cases. Fluorescence in situ hybridization analysis showed BCL6, MYC , and BCL2 rearrangements in 11 of 32 (34%), 8 of 27 (30%), and 11 of 50 (22%) cases, respectively.
These results add to what is known about the geographic variation of diffuse large B-cell lymphomas. In northern China, the frequency of the germinal center B-cell-like type and BCL6 expression and/or BCL6 rearrangement is less and the frequency of MYC rearrangement is greater than have been reported in Western countries.

Download full-text

Full-text

Available from: Peter Chi Hu, Aug 30, 2015
0 Followers
 · 
88 Views
  • 09/2012; 3(2):117-126. DOI:10.1007/s12308-010-0069-1
  • [Show abstract] [Hide abstract]
    ABSTRACT: Non-Hodgkin lymphomas (NHLs) are neoplasms that arise from lymphocytes of either B- or T-cell lineage or rarely from histiocytes. The anatomic location and many of the biologic features of various NHL types can be related to their normal counterparts. Normal B-cells are concentrated in the follicles and medullary cords of lymph nodes and in the follicles of the spleen [1]. The lymphoid follicles represent the proliferative site of the B-cell system. Upon antigen stimulation, secondary germinal centers develop in which rapid cell division of B-cells takes place. The medullary cord region of the lymph node represents the secretory component of the B-cell system. By contrast, T-cells are selectively concentrated in the paracortical regions of lymph nodes and within the periarterial lymphoid sheaths of the spleen. In addition, small numbers of T-cells are found within follicles where they help in the induction of B-cell differentiation [2, 3]. Histiocytes are preferentially found in the subcapsular and medullary sinuses of lymph nodes and the cords of Billroth in the splenic red pulp. Histiocytes are also a part of the reticuloendothelial system of the liver and lung. Tissue histiocytes have two broad categories of function. Most histiocytes are phagocytic, whereas a minority of specialized cells is involved in antigen processing and presentation to B- and T-cells [4].
    Neoplastic Diseases of the Blood, 01/2013: pages 867-918; , ISBN: 978-1-4614-3763-5
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: Little is known on racial differences in patients with diffuse large B-cell lymphoma (DLBCL). The aim of this retrospective study is to compare characteristics, prognostic factors and outcomes of Asian and Western patients with DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). METHODS: Patient-level data was collected from 8 centers. All patients were diagnosed with DLBCL and treated with R-CHOP. Patients were divided into Asian and Western, according to the country of report. Comparisons and univariate/multivariate survival analyses were performed. RESULTS: 712 patients, 455 Asian and 257 Western patients were included. Westerners were more likely to present with elevated LDH (64% vs. 48%, p<0.01) and advanced stage (58% vs. 49%, p<0.01). After a median follow-up of 36 months, there was no difference in progression-free (PFS; p=0.33) or overall survival (OS; p=0.69). There were no PFS or OS differences between races when evaluating separately each age-adjusted International Prognostic Index category. In the multivariate analyses, performance status and stage were associated with PFS and OS in both races. CONCLUSIONS: There are no differences in prognostic factors, PFS and OS between Asian and Western patients with DLBCL treated with R-CHOP.
    Leukemia research 01/2013; 37(4). DOI:10.1016/j.leukres.2013.01.002 · 2.69 Impact Factor
Show more